Open AccessEfficacy of degarelix in prostate cancer patients following failure on luteinizing hormone-releasing hormone agonist treatment: results from an open-label, multicentre, uncontrolled, phase II trial (CS27)
Author(s) -
Kurt Miller,
Gabriele Simson,
Sandra Goble,
BoEric Persson
Publication year - 2015
Publication title -
therapeutic advances in urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.115
H-Index - 30
eISSN - 1756-2880
pISSN - 1756-2872
DOI - 10.1177/1756287215574479
Subject(s) - medicine , prostate cancer , clinical endpoint , cohort , hormone antagonist , urology , hormonal therapy , adverse effect , cancer , oncology , hormone , randomized controlled trial , endocrine system
To evaluate the efficacy of second-line degarelix in patients with prostate cancer (PCa) after treatment failure with a luteinizing hormone-releasing hormone (LHRH) agonist.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom